Navigation Links
Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association

SOUTH SAN FRANCISCO, Calif., June 01, 2007 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today announced that the company will present data from ongoing clinical studies of SNS-595 and SNS-032 at the 12th Congress of the European Hematology Association (EHA) being held June 7-10, 2007 in Vienna, Austria.

Presentations will include updated interim data from the company's Phase 1 clinical trial of SNS-595 in acute leukemias, as well as clinical data from an ongoing study of SNS-032 further detailing that compound's mechanism of action.

    -- Abstract #0489: "Pharmacokinetic/Pharmacodynamic Correlation with

       Responses in a Phase 1 Study of Patients with Relapsed/Refractory Acute

       Leukemias Treated with SNS-595" will be presented on Saturday, June 9,

       2007 from 6:00-7:15 p.m. during the Acute Myeloid Leukemia -- Clinical

       II poster session.


    -- Abstract #0742: "SNS-032 Exhibits Dose-Dependent Mechanism-Based

       Inhibition of CDK7 and CDK9 in Peripheral Blood Mononuclear Cells from

       Patients with Advanced Cancers Treated in an Ongoing Phase 1 Trial"

       will be presented on Saturday, June 9, 2007 from 6:00-7:15 p.m. during

       the Novel Therapeutics and Targeted Therapies poster session.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. Sunesis is currently conducting Phase 2 clinical trials in lung and ovarian cancer and a Phase 1 clinical trial in acute leukemias for its lead compound, SNS-595. SNS-032, a selective inhibitor of cyclin-dependent kinases 7 and 9, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors. The company's Aurora kinase inhibitor, SNS-314, is expected to begin Phase 1 clinical trials in the first hal
'"/>




Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:5/16/2008)...sults demonstrating that TYKERB and trastuzumab to...on of progression-free survival (PFS), -- Combini...e and,outside of the HER2 receptor may create a mo...activity of TYKERB alone despite patients,previou... chemotherapy, LONDON and PHILADELPHIA, May 16 /P...
(Date:5/16/2008)...tically Significant Reductions in Selected ...to be published in 2008 Proceedings of the America...cology, SAN DIEGO, May 16 /PRNewswire-FirstCall/ ...nounced today that, in a registrational bioequival...tically significant reduction,in general disorders...
(Date:5/15/2008)...ta highlight safety profile of BSI-201 in ...ISBANE, Calif., May 15 /- BiPar Scien...any developing novel cancer therapies,today annou... BSI-201, will,be presented at the 2008 American S...ago., Findings will be presented from the first i...
(Date:5/15/2008)...RNewswire-FirstCall/ -- Schering-Plough,Corporatio... and treatment of,chronic hepatitis C virus (HCV) ...clinical studies with PEGINTRON(TM) (peginterferon...ion therapy, as well as boceprevir, the,company,s ...be presented at,the 39th annual Digestive Disease ...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Baltimore Washington Medical Center Hosts Day of Dance for Health 10732 1Baltimore Washington Medical Center Hosts Day of Dance for Health 10732 2Study finds widespread vitamin and mineral use among cancer survivors 10729 1Study finds widespread vitamin and mineral use among cancer survivors 10729 2Unilens Vision Inc Declares Regular Quarterly Cash Dividend of U S 240 09 Per Share 10722 1Unilens Vision Inc Declares Regular Quarterly Cash Dividend of U S 240 09 Per Share 10722 2Unintended Errors Leave Many Newborns Vulnerable 10721 1Unintended Errors Leave Many Newborns Vulnerable 10721 2
...Future Trials, Other,Programs --, GAITHERSBURG, Md...-FirstCall/ -- Iomai Corporation today announced r...ial of its patch-based,vaccine for travelers, diar...y of a range of vaccine doses to generate an immun...bacteria -- the,most common cause of travelers, di...
...6, 2007 - Columbia,Laboratories, Inc. (NASDAQ: CBR...he ongoing data analysis of the recently-completed...e III clinical,trial of PROCHIEVE(R) 8% (progester...men with a previous preterm birth earlier than,35 ...PROCHIEVE 8%,in delaying cervical shortening. A sh...
Other Medicine Technology:Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for,Travelers' Diarrhea Stimulates Immune Response Even at Low Doses 2Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for,Travelers' Diarrhea Stimulates Immune Response Even at Low Doses 3Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for,Travelers' Diarrhea Stimulates Immune Response Even at Low Doses 4Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 2Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 3
(Date:5/16/2008)...Newswire/ -- Less than a week after,committing med...stated by,Cyclone Nargis, Project HOPE, an interna...e organization, is again mobilizing its full,resou...or the people of,central China devastated by the m...ives., "I am saddened by the vast loss of life an...
(Date:5/16/2008)...people who didn,t have cancer as children, study f... -- Adults who had cancer as children or teens are... a new study found. , And the heart problems s...d not suffer cancer as children. , Childhood ca...mes increased risk of having heart disease compare...
(Date:5/16/2008)...t The University of Texas M. D. Anderson Cancer Ce... leukemia cells by shutting down their energy sour...ical study, Lauren Akers, D.O., postdoctoral fello...erson, found that combining a novel glycolysis inh...duced more than 90 percent cell death in human tis...
(Date:5/16/2008)...hs School of Nursing and Midwifery, has won the In...an Nursing Awards. , Professor Rickard won top ... during testing procedures, reducing the risk of a...lready ill patients. The award was announced last ...inment complex. , Nurses routinely take blood s...
Breaking Medicine News(10 mins):Health News:Project HOPE to Send Humanitarian Assistance to China as Humanitarian Assistance to Myanmar Continues 2Health News:Childhood Cancer Survivors Prone to Early Heart Trouble 2Health News:Childhood Cancer Survivors Prone to Early Heart Trouble 3Health News:New drug combination brings 1-2 punch against acute leukemia 2Health News:Research talent wins national Innovation in Nursing award 2
...chers are conducting a study to find out ways to i...eople. // Pfizer Australia Cardio Vascular Lipid (...r Clair Sullivan from the Centre for Diabetes and ... Queensland and Princess Alexandra Hospital for th...
...t difference found with respect to major clinical ...ng C-section. Some women, however had lower blood...ral anesthesia and some experienced more nausea an...This was the first such review to consider both ne...
...main culprit for nerve fibre damage in multiple sc...ne system, which is vital for early diagnosis // a.... The study indicated the manner in which immune s...tacks by hampering the energy production in nerve ...
...emonstrated how intense struggle among the human i...us to survive harm and take on a more virulent for... The study, which uses a computer model of simulta...es a hint of a new strategy for using vaccines aga...
Other Medicine News:Health News:Choice of Anesthesia in C-section 2Health News:Choice of Anesthesia in C-section 3Health News:Basis for Nerve fiber Damage in Multiple Sclerosis Discovered 2Health News:Basis for Nerve fiber Damage in Multiple Sclerosis Discovered 3Health News:HIV Takes Advantage of Rivalry among T cells 2Health News:HIV Takes Advantage of Rivalry among T cells 3
The Shandon Manual Staining Station is ideal for special processes, frozen sections, special stains and low volume procedures.
The Shandon Finesse 315 low-cost precision microtome is ergonomically designed to consistently produce high quality routine paraffin sections without user strain or fatigue.
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor.
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains.
Medicine Products: